Skip to main content

Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  •  Leading neurologists and stroke specialists here on Thursday urged women to seek immediate medical attention in case of "mini-strokes" as delaying treatment could increase risk of a major stroke.

  • In a joint survey conducted by PHD Chamber of Commerce and Industry and 1mg Technologies on challenges faced by consumers while buying medicines from Pharmacies, it has been stressed that an overwhelming majority of patients seek more convenient ways to get their medicine. They face problem of visiting multiple pharmacies to get all their medicines and also notice price difference across pharmacies for the same drug.

  • - 50% of ALF cases happen due to Hepatitis A&E, unavailability of clean potable water

    - ALF mortality has come down to 20 % from 80 % in last 10 years due to advancement in liver intensive care and liver transplantation of ALF patients.

    (NewsVoir); The expert team of Department of Hepatology at Global Hospitals - one of the fastest growing chains of multi-super speciality, multi-organ transplant and quaternary care hospitals in Mumbai, shared their experience in treating and managing Acute Liver Failure patients medically and through transplantation.

    [adsense:336x280:8701650588]

  • Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in Montreal. One analysis showed significant lung function improvement, as measured by FEV1 AUC0–3, with once daily Spiolto® Respimat® in COPD patients* across a range of age groups, including those over 65 years of age.1 In addition, a second analysis indicated that Spiolto® Respimat® reduces the frequency of night-time rescue medication use, as measured by puffs needed per night2 and these reductions were sustained for up to 52 weeks. In a third analysis the improvement of dyspnea (or shortness of breath), as measured by the Transition Dyspnea Index (TDI), was shown in COPD patients, compared to tiotropium, olodaterol and placebo.3

Subscribe to Pharma News